A Phase I Trial of Regorafenib and Cetuximab in Patients With Advanced Malignancy
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 May 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Regorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 24 May 2019 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2016 Status changed from active, no longer recruiting to recruiting according to ClinicalTrials.gov.